Dr. Virginia Kaklamani, Medicine/Hematology-Oncology and Mays Cancer Center, is the moderator of the discussion presented below. This is the final installment of a four-part series. The experts comment on two phase III trials that could change the treatment landscape for patients with metastatic HER2-positive breast cancer.